page 28 - Industrail affairs: the power of global capacity

Industrial Affairs: the power of global capacity

Sanofi-aventis can rely on a strong industrial presence to develop its portfolio and drive diversification forward in emerging countries and other markets. Sanofi-aventis can rely on a strong industrial presence to develop its
portfolio and drive diversification forward in emerging countries and other
markets.

Industrial strategy is essential to sanofi-aventis’ expansion. In 2009, Industrial Affairs stepped up its performance fundamentals in terms of quality, safety, environmental friendliness, customer service and business competitiveness. In developed countries, the Group continued to optimize technology skills in its industrial facilities in 2009, especially by investing in two new production lines for Lantus® at its Frankfurt site (Germany), developing medicine lifecycle management with new presentations of Doliprane® and Maalox®, and boosting production capacity for Lovenox®. Industrial strategy is essential to sanofi-aventis’ expansion. In 2009,
Industrial Affairs stepped up its performance fundamentals in terms of quality,
safety, environmental friendliness, customer service and business
competitiveness. In developed countries, the Group continued to optimize
technology skills in its industrial facilities in 2009, especially by
investing in two new production lines for Lantus® at its Frankfurt site
(Germany), developing medicine lifecycle management with new presentations of
Doliprane® and Maalox®, and boosting production capacity for Lovenox®.

It also re-purposed two of its historic sites as biotechnology facilities, creating a unit in Vitry-sur-Seine (France) and establishing the first center for the production of dengue fever vaccines in Neuville-sur-Saône (France). In emerging countries, the Group’s growth now relies on industrial sites with a strongly regional focus, notably in Brazil and Mexico, which will be further strengthened by acquisitions in 2009. With Kendrick in Mexico and Medley in Brazil, sanofi-aventis is now in a commanding industrial position. It also re-purposed two of its historic sites as biotechnology facilities,
creating a unit in Vitry-sur-Seine (France) and establishing the first center
for the production of dengue fever vaccines in Neuville-sur-Saône (France). In
emerging countries, the Group’s growth now relies on industrial sites with a
strongly regional focus, notably in Brazil and Mexico, which will be further
strengthened by acquisitions in 2009. With Kendrick in Mexico and Medley in
Brazil, sanofi-aventis is now in a commanding industrial position.

An industrial approach on a global scale

The Group now has a comprehensive industrial infrastructure, comprising global sites dedicated to the manufacture of medical devices, systems and high technology products such as Lantus®, Multaq® and Lovenox®; brand-driven regional sites producing consumer products in large volumes; and local plants focused on their national markets. The Group now has a comprehensive industrial infrastructure, comprising global
sites dedicated to the manufacture of medical devices, systems and high
technology products such as Lantus®, Multaq® and Lovenox®; brand-driven
regional sites producing consumer products in large volumes; and local plants
focused on their national markets.

To oversee the growth of its industrial base, the Group introduced a unique Quality policy in 2009, as well as an international, cross-functional quality assurance structure with teams from R&D, Industrial Affairs, sanofipasteur and Pharmaceutical Operations. In parallel, an Industrial Development and Innovation division was created in June 2009 tasked with managing the lifecycle of the entire portfolio (Innovative Medicines, Consumer Healthcare, Generics and Medical Devices). The aim is to develop products and delivery systems that address as yet unmet medical needs and respond to patients’ expectations around the world. To oversee the growth of its industrial base, the Group introduced a unique
Quality policy in 2009, as well as an international, cross-functional quality
assurance structure with teams from R&D, Industrial Affairs, sanofipasteur and
Pharmaceutical Operations. In parallel, an Industrial Development and
Innovation division was created in June 2009 tasked with managing the
lifecycle of the entire portfolio (Innovative Medicines, Consumer Healthcare,
Generics and Medical Devices). The aim is to develop products and delivery
systems that address as yet unmet medical needs and respond to patients’
expectations around the world.

KEY FIGURES

€350 million will be invested in the Neuville-sur-Saône site to create a production center for the first vaccine against dengue fever. €350 million will be invested in the Neuville-sur-Saône site to create a
production center for the first vaccine against dengue fever.

3.5 billion packages of medicines were manufactured by sanofi-aventis worldwide in 2009. 3.5 billion packages of medicines were manufactured by sanofi-aventis worldwide
in 2009.

FOCUS

AWARDS FOR INDUSTRIAL INNOVATION

To encourage innovation as the key to sanofi-aventis’ competitiveness, the Industrial Affairs division launched its Innovation Awards in 2009, attracting for this first round 280 internal projects, 18 of which were shortlisted and six selected as winners by the jury. To encourage innovation as the key to sanofi-aventis’ competitiveness, the
Industrial Affairs division launched its Innovation Awards in 2009, attracting
for this first round 280 internal projects, 18 of which were shortlisted and
six selected as winners by the jury.